Mr. Mariusz Olejniczak reports

WPD PHARMACEUTICALS PROVIDES UPDATE ON WPD101, A DRUG CANDIDATE TARGETING GBM TUMORS

In celebration of last week's national glioblastoma multiforme (GBM) day in the United States, WPD Pharmaceuticals Inc. has provided an update on its WPD101 drug candidate.

WPD101 is a recombinant fusion protein helping in the treatment of GBM, one of the most aggressive malignant tumours of the central nervous system that arises from normal glial cells. Development of WPD101 will allow GBM patients access to innovative molecular targeted therapies as an alternative to conventional treatment.

WPD is developing a WPD101 fixed combination product based on its licence agreement with Wake Forest University, a leading private research university in North Carolina. The WPD101 product includes two active pharmaceutical ingredients, one of which is called WPD101a, a chimeric cytotoxin composed of a tumour-targeting recombinant molecule that is a mutated form of human interleukin 13 (IL-13(E13KR66D)) fused to the enzymatically active portion of modified diphtheria toxin (DT).

The breakthrough of WPD's solution is that WPD101a binds specifically to IL-13a2 receptors overexpressed on GBM cells. Binding of WPD101a to IL-13Ra2-expressing tumour cells is followed by internalization of the formed complex and intracellular release of cytotoxic DT through proteolytic cleavage. Within the cytosol, enzymatically active DT is translocated into the endoplasmic reticulum, where it inactivates eEF2, thus inhibiting protein synthesis and inducing cancerous cell death.

On June 26, 2020, WPD took part in a non-clinical scientific advice meeting with MHRA (Medicines & Healthcare Products Regulatory Agency) in the United Kingdom, presenting the results of the research and development work from its in-house production, preliminary preclinical results on mice, and the further WPD101a development plan. On July 23, 2020, WPD received a scientific advice letter from MHRA in response to the meeting. The agency confirmed the company's preclinical development plan.

About WPD Pharmaceuticals Inc.

WPD is a biotechnology research and development company with a focus on oncology and virology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has licensed in certain countries 10 novel drug candidates, with four that are in the clinical development stage. These drug candidates were researched at institutions, and WPD currently has continuing collaborations with Wake Forest University and leading hospitals and academic centres in Poland.

We seek Safe Harbor.